We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
According to Nosophorm, the initial focus will be on Chemistry, Manufacturing and Control (CMC) as well as Clinical Trial Application (CTA)-enabling and filing activities related to NOSO-502